SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma

NCT07374549 | Not Yet Recruiting Phase 2

• 1 other identifier: SYS6002-00X
• Study Type: interventional
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study is a randomized, open-label, controlled, multicenter phase II clinical trial, which aims to evaluate the safety and efficacy of SYS6002 versus enfortumab vedotin in the treatment of participants with advanced urothelial carcinoma. This study has not yet been submitted for ethical review. The current registration is a pre-registration. Recruitment will be initiated only after formal approval is obtained from the relevant Ethics Committee or Institutional Review Board.

Conditions

Advanced Urothelial Carcinoma

Outcome Measures

Primary Outcomes (1)

• Occurrence and frequency of Adverse Event (AE)

  Up to approximately 2 years

Secondary Outcomes (8)

• Incidence of treatment-related peripheral neuropathy and≥1-grade worsening in treatment-related peripheral neuropathy from baseline

  Up to 2 years

• Incidence of treatment-related hyperglycemia

  Up to 2 years

• Incidence of treatment-related cutaneous adverse reactions

  Up to 2 years

• Objective Response Rate (ORR)

  Up to 2 years

• Duration of Response (DOR)

  Up to 2 years

Study Arms (2)

SYS6002

ACTIVE COMPARATOR

Drug: SYS6002

enfortumab vedotin

ACTIVE COMPARATOR

enfortumab vedotin monotherapy

Drug: enfortumab vedotin

Interventions

SYS6002 DRUG

SYS6002 by intravenous (IV)

SYS6002

enfortumab vedotin DRUG

1.25 mg/kg by IV on Day 1、8、15, every 28 days.

enfortumab vedotin

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Patients aged 18-80 years (inclusive);
• \. Pathologically confirmed patients with advanced urothelial carcinoma who have received a platinum-based chemotherapy with anti-PD-(L)1 agent. For those who received these therapies in the adjuvant or neoadjuvant setting, disease progression must have occurred during treatment or within 12 months of treatment completion;
• An archival tumor tissue sample or a fresh tissue sample should be provided;
• Subjects must have measurable disease according to RECIST (version 1.1);
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
• Life expectancy of ≥ 3 months;
• Major organ function must meet the relevant laboratory test standards for hematology, renal function, liver function, and coagulation within 7 days prior to treatment;
• Sexually active fertile subjects must agree to use methods of contraception during the study and at least 7 months after termination of study therapy and have a negative urine or serum pregnancy test within 7 days prior to randomization;
• Willing to participate in the study, understand the study procedures, and sign a written informed consent form.

You may not qualify if:

• Active central nervous system metastases or leptomeningeal metastasis;
• Adverse events from prior anti-tumor therapy not recovered to ≤ Grade 1 (unless the investigator deems there is no safety risk)；
• Any serious and/or uncontrolled concurrent illness that may interfere with patient's participation in the study:
• Participants with a history of severe cardiovascular disease within 6 months prior to randomization, including but not limited to:
• Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia and third-degree atrioventricular block requiring clinical intervention; corrected QT interval \> 480 ms by Fridericia method (Fridericia formula: QTcF = QT/RR\^0.33, RR = 60/heart rate); With history of myocardial infarction, unstable angina pectoris, angioplasty and coronary artery bypass surgery; New York Heart Association (NYHA) classification Grade III and above heart failure, and left ventricular ejection fraction (LVEF) \< 50% in the tests and examinations during the screening period; cerebrovascular accidents; pulmonary embolisms;
• Other clinically significant diseases:
• HbA1c \> 8%; Participants with active keratitis and corneal ulcer, or fundus lesions with a risk of blindness; Grade ≥2 neuropathy prior to randomization; Severe infection within 4 weeks prior to randomization; active infection requiring systemic antibiotics, antiviral, or antifungal therapy within 2 weeks prior to randomization; Active HBV or HCV infection; History of immunodeficiency (HIV-positive, acquired or congenital immunodeficiency, etc.), or organ transplantation; History of another malignancy within 3 years prior to randomization; History of interstitial lung disease (ILD) / non-infectious pneumonia, or current ILD/non-infectious pneumonia, or imaging findings at screening that cannot rule out these conditions, except for those who are determined to be risk-free after discussion between the investigator and the sponsor; Pleural effusion, ascites or pericardial effusion with symptoms or requiring puncture or drainage within 2 weeks prior to randomization;
• Use of other unmarketed clinical investigational drugs or treatments, chemotherapy, radiotherapy targeted therapy within 4 weeks prior to randomization; use of traditional Chinese medicine with anticancer indication, oral fluoropyrimidine drugs, small molecule targeted drug within 2 weeks prior to randomization; use of palliative radiation or local therapy within 2 weeks prior to randomization;with major surgery within 4 weeks prior to randomization;
• Allergy to any component of SYS6002, or humanized monoclonal antibodies; investigator-determined ineligibility for enfortumab vedotin therapy.
• \. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.

Sponsors & Collaborators

• CSPC Megalith Biopharmaceutical Co.,Ltd.: lead

MeSH Terms

Interventions

enfortumab vedotin

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Participants in this trial will be randomly assigned to one of two groups.

Study Record Dates

• First Submitted: January 21, 2026
• First Posted: January 29, 2026
• Study Start (Estimated): June 20, 2026
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): December 1, 2028
• Last Updated: January 29, 2026

Record last verified: 2026-01